Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Profile Name||RUNX1 mutant|
|Gene Variant Detail|
|Relevant Treatment Approaches|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|RUNX1 mutant||essential thrombocythemia||not applicable||N/A||Guideline||Prognostic||The presence of at least one mutation in either SH2B3, IDH2, U2AF1, SRSF2, SF3B1, EZH2, TP53, or RUNX1 is associated with inferior overall survival in patients with essential thrombocythemia (NCCN.org).||detail...|
|RUNX1 mutant||myelodysplastic syndrome||not applicable||N/A||Clinical Study||Prognostic||In clinical analyses, RUNX1 mutations were associated with poor overall survival in patients with myelodysplastic syndrome (PMID: 21714648, PMID: 22869879).||22869879 21714648|
|RUNX1 mutant||myelodysplastic syndrome||not applicable||N/A||Guideline||Prognostic||RUNX1 mutations are associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).||detail...|
|RUNX1 mutant||polycythemia vera||not applicable||N/A||Guideline||Prognostic||RUNX1 mutations are associated with inferior overall survival and leukemia-free survival in patients with polycythemia vera (NCCN.org).||detail...|
|RUNX1 mutant||acute myeloid leukemia||not applicable||N/A||Clinical Study||Prognostic||In clinical analyses, RUNX1 mutations were associated with adverse clinical outcome in acute myeloid leukemia patients (PMID: 21343560, PMID: 22689681, PMID: 22753902, PMID: 25652455).||21343560 25652455 22689681 22753902|
|RUNX1 mutant||acute myeloid leukemia||not applicable||N/A||Guideline||Prognostic||RUNX1 mutations are associated with a poor/adverse prognosis in patients with non-APL acute myeloid leukemia (NCCN.org).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03383575||Phase II||Azacitidine + Enasidenib Enasidenib||Targeted Therapy With the IDH2-Inhibitor Enasidenib (AG221) for High-Risk IDH2-Mutant Myelodysplastic Syndrome||Recruiting|
|NCT03365661||Phase II||ALT-803||QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML||Withdrawn|
|NCT03047993||Phase Ib/II||Azacitidine + Telaglenastat||Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome||Recruiting|
|NCT03932643||Phase I||ONC201||ONC 201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant||Recruiting|
|NCT03613532||Phase I||Busulfan + Fludarabine + Venetoclax||Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN||Recruiting|